Three incretin-based research peptides dominate metabolic research discussions in 2026: semaglutide, tirzepatide, and retatrutide. They are frequently compared because each adds an additional receptor target, and each has been associated with progressively larger effects in published clinical research. This guide compares their mechanisms, research context, and handling considerations for laboratory researchers.
Mechanism at a glance
| Compound | Receptor targets | Class | Reported research weight-reduction magnitude* |
|---|---|---|---|
| Semaglutide | GLP-1 | Single agonist | ~15% over 68 weeks |
| Tirzepatide | GLP-1 + GIP | Dual agonist | ~20-22% over 72 weeks |
| Retatrutide | GLP-1 + GIP + glucagon | Triple agonist (triagonist) | up to ~24% over 48 weeks |
Semaglutide (GLP-1 receptor agonist)
Semaglutide is a single GLP-1 receptor agonist and the most extensively characterized of the three in the research literature. It is widely used as a reference compound in metabolic, glucose-regulation, and appetite-signaling research models. Explore Semaglutide research peptide.
Tirzepatide (GLP-1 / GIP dual agonist)
Tirzepatide adds GIP-receptor activity to the GLP-1 mechanism. This dual-incretin approach has been associated with larger effects than single GLP-1 agonism in comparable trials, making it a common comparator in dual-receptor research. Explore Tirzepatide research peptide.
Retatrutide (GLP-1 / GIP / glucagon triple agonist)
Retatrutide is a triagonist that adds glucagon-receptor activity on top of GLP-1 and GIP. In published Phase 2 research it has been associated with the largest reported reductions of the three, alongside a higher reported frequency of adverse events. It remains investigational. Explore Retatrutide research peptide.
Reconstitution and handling
All three are supplied as lyophilized powders and are reconstituted with bacteriostatic water for research handling. Store lyophilized material at -20°C and keep out of direct light.
Verifying quality: read the COA
For any research peptide, the Certificate of Analysis (COA) is the primary quality signal. Look for a lot number that matches your vial, an HPLC purity figure, mass-spectrometry identity confirmation, and endotoxin testing. Every Greatest Peptides order includes batch-specific COA documentation for the exact lot shipped.
Summary
Semaglutide, tirzepatide, and retatrutide represent a progression from single to dual to triple incretin-receptor agonism, with correspondingly larger reported effects in published research. The right choice for a study depends on the receptor pathways under investigation.
All products referenced are sold strictly for laboratory and research use only. Not for human or animal consumption. This article summarizes publicly reported research and is not medical advice.